Research Grade Romosozumab ( 洛莫索珠单抗 )
- 发布日期: 2020-10-28
- 更新日期: 2025-10-24
产品详请
| 产地 |
中国
|
| 品牌 |
Chemstan
|
| 货号 |
CSD00275
|
| 保存条件 |
store at -80℃
|
| 用途 |
仅用于科研用途
|
| 应用范围 |
|
| 抗原来源 |
CHO cells
|
| CAS编号 |
909395-70-6
|
| 保质期 |
一年
|
| 抗体名 |
Romosozumab ( 洛莫索珠单抗 )
|
| 是否单克隆 |
|
| 克隆性 |
|
| 靶点 |
SOST[Homo sapiens]
|
| 适应物种 |
|
| 形态 |
|
| 宿主 |
|
| 标记物 |
|
| 包装规格 |
1mg/ml
|
| 纯度 |
%
|
| 亚型 |
|
| 标识物 |
|
| 浓度 |
95%
|
| 免疫原 |
|
| 是否进口 |
否
|
Romosozumab is a humanized monoclonal antibody indicated for the treatment of osteoperosis in postmenopausal women at high risk of fracture and patients who have failed in other treatments or are intolerant to other osteoperosis therapies9. Romosozumab prevents bone resorption and induces the formation of bone though it is associated with an increased risk of cardiac death, heart attack, and stroke in one study7,8. In a comparison study of post menopausal women with osteoporosis and a past fracture, romosozumab for 12 months followed by alendronic acid for 12 months was superior to alendronic acid alone for 24 months3. Romosozumab also demonstrates a faster and larger increase in bone density than teriparatide4. Romosozumab is marketed in the United States by Amgen under the brand name Evinity7. Romosozumab was granted FDA approval on April 9,2019.
货号(Catalog No.)
CSD00275
通用名INN
Romosozumab
纯度(Purity)
>95%
浓度( Concentration)
1mg/ml
Formulation
PBS buffer pH7.5
Source
CHO cells
内毒素(Endotoxin level)
Please contact with the lab for this information.
生物活性
产品描述(Description)
Romosozumab is a humanized monoclonal antibody indicated for the treatment of osteoperosis in postmenopausal women at high risk of fracture and patients who have failed in other treatments or are intolerant to other osteoperosis therapies9. Romosozumab prevents bone resorption and induces the formation of bone though it is associated with an increased risk of cardiac death, heart attack, and stroke in one study7,8. In a comparison study of post menopausal women with osteoporosis and a past fracture, romosozumab for 12 months followed by alendronic acid for 12 months was superior to alendronic acid alone for 24 months3. Romosozumab also demonstrates a faster and larger increase in bone density than teriparatide4. Romosozumab is marketed in the United States by Amgen under the brand name Evinity7. Romosozumab was granted FDA approval on April 9,2019.
别名(Alternative names)
785A070802,AMG 785,CDP-7851,romosozumab-aqqg,sclerostin Ab
靶点;物种(Specificity target name;species)
SOST[Homo sapiens]
种类(Species)
Humanized
受体鉴定(Receptor identification)
IgG2-kappa
化学信息
分子量(MV)
145805.0 Da
CAS
909395-70-6
存储条件(Storage)
store at -80°C
Note
For research use only. Not suitable for clinical or therapeutic use.